Genetics of Peripheral Artery Genomics
Peripheral artery disease is a disease that contributes to significant morbidity and mortality of millions of Americans yearly. Very little is known about the pathophysiology of atherosclerosis in peripheral artery disease. We plan to collect peripheral arteries and muscle tissue from patients undergoing amputation for end stage peripheral arterial occlusive disease. By extracting the RNA from these arteries and tissues and comparing them with RNA expression from normal arteries, we hope to have a better understanding of the pathophysiology of atherosclerosis in this setting. We aim to prove the hypothesis that a novel gene expression pattern can be discovered by the successful extraction of RNA from plaques from human peripheral arteries.
Peripheral Artery Disease
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Genetics of Peripheral Artery Disease|
- Discover novel gene expression pattern in peripheral arterial disease [ Time Frame: ongoing ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Peripheral artery samples collected from patients are stored in -80celcius refrigerator for future analysis.
|Study Start Date:||June 2004|
|Estimated Study Completion Date:||July 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
arteries from PAD patients
peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease
arteries from Free Fib transfers
peripheral arteries from patients without evidence of peripheral arterial occlusive disease
Patients scheduled to undergo lower extremity amputation will be consented for extraction of plaque from the carotid artery or arterial tissue from the amputated limbs. The surgeon will perform the amputation, then the harvest team will collect arterial tissue from amputated limbs. These samples will be immersed in RNALater solution to preserve the integrity of the RNA. Tissues will stored at -80oC in the RNALater until the RNA is later extracted using a standardized protocol. The RNA will be examined for quality using an Agilent bioanalyzer, and will then be processed on Affymetrix U133A chips for gene expression data. The data will be analyzed with the MATLAB software package.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00615121
|Contact: Dana Giangiacomo||(919) firstname.lastname@example.org|
|United States, North Carolina|
|Duke University Medical Center||Recruiting|
|Durham, North Carolina, United States, 27710|
|Principal Investigator: Jeffrey H Lawson, MD, PhD|
|Principal Investigator:||Jeffrey H Lawson, MD, PhD||Duke University|